No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic cough drug after unsuccessful results late-stage clinical trial.
Refractory chronic cough or RCC is a persistent cough lasting more than eight weeks, and is known as an under-recognised disease with limited treatment options.
GSK's Camlipixant treatment, a P2X3 receptor antagonist, was evaluated in adults with RCC in the CALM-1 and CALM-2 phase III clinical trials.
While CALM-1 met its primary endpoint, showing statistically significant reductions in 24-hour cough frequency when taking 50mg of camplixant twice daily versus the placebo after 12 weeks, the 24-week CALM-2 study did not. Meanwhile, the 25mg dose of camplixant twice daily didn't show any statistical significance in either study, GSK said.
Overall incidence rates and severity of treatment-related adverse events were seen to be similar to the placebo in both trials.
"Based on the aggregate data, the limited efficacy demonstrated is unlikely to transform patient care. GSK has decided not to progress further development of camlipixant in RCC," GSK said in a statement.
"Results from the CALM phase III programme will be submitted for future presentation/publication to contribute to the scientific understanding of RCC."
The stock was down 3.8% at 1,882p by 1225 BST.
See the latest RNS on Investegate.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.